Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Chiarenza, Annalisa  [Clear All Filters]
2016
Giallongo C, Tibullo D, Parrinello NL, La Cava P, Di Rosa M, Bramanti V, Di Raimondo C, Conticello C, Chiarenza A, Palumbo GA, et al. Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). Oncotarget. 2016.
2021
Morabito F, Tripepi G, Del Poeta G, Mauro FRomana, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Varettoni M, et al. Assessment of the 4-factor score: retrospective analysis of 586 cll patients receiving ibrutinib. A campus cll study. Am J Hematol. 2021.
Boccomini C, Ladetto M, Rigacci L, Puccini B, Rattotti S, Volpetti S, Ferrero S, Chiarenza A, Freilone R, Novo M, et al. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). Br J Haematol. 2021.
Morabito F, Tripepi G, Del Poeta G, Mauro FRomana, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, et al. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials. Am J Hematol. 2021.
Morabito F, Del Poeta G, Mauro FRomana, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, et al. TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases. Am J Hematol. 2021.
2022
Fresa A, Autore F, Piciocchi A, Catania G, Visentin A, Tomasso A, Moretti M, Vitale C, Chiarenza A, Morelli F, et al. Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. Blood Adv. 2022;6(13):3875-3878.
2023
Sportoletti P, Laurenti L, Chiarenza A, Gaidano G, Albi E, Mauro FRomana, Trentin L, Vallisa D, Pane F, Cuneo A, et al. Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study. Hematol Oncol. 2023.
2024
Duminuco A, Romano A, Ferrarini I, Santuccio G, Chiarenza A, Figuera A, Caruso LAnastasia, Motta G, Palumbo GAlberto, Mogno C, et al. Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey. Ann Hematol. 2024.